Guided Therapeutics Non-Invasive Cervical Cancer Detection Device Trial Confirms Current Tests Miss Disease; Create High False Positive Rates

Preview of FDA Pivotal Clinical Trial Results Presented at National Cancer
Institute Conference
BOSTON--(Business Wire)--
Results of the FDA pivotal clinical trial for the LightTouch Non-invasive
Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT)
(Pink Sheets: GTHP), indicated that the current system for diagnosing cervical
disease missed the same amount of disease as a landmark study carried out by the
National Cancer Institute (NCI).

In the new LightTouch study, conducted at six US clinics and with an enrollment
of approximately 2,000 women, 32% of cervical precancers and cancers were missed
by the current method of human papillomavirus (HPV) testing and colposcopy,
while only 19% of biopsy samples indicated the presence of these diseases.
Similarly, the ASCUS/LSIL Triage Study for Cervical Cancer (ALTS), sponsored by
NCI, indicated that approximately 35% of disease was missed and only about 26%
of biopsies found significant disease. Both ALTS and the LightTouch study used
follow up data to estimate the number of missed disease cases when the original
diagnosis was rendered.

"ALTS sheds new light on problems plaguing cervical disease management after a
women undergoes Pap screening and adjunctive tests, such as HPV and colposcopy,"
said Mark L. Faupel, Ph.D., President and CEO of GT. "Our FDA study confirms the
ALTS results and shows the high rate of false positives and false negatives
using conventional procedures and technology."

The results were presented at NCI`s inaugural Investor Forum at Boston
University. GT was selected as one of NCI`s top innovators. GT has been awarded
approximately $6 million in six consecutive grants from the NCI to develop the
new, pain-free test for detecting cervical disease.

The GT LightTouch technology systematically and rapidly scans the cervix to
identify cancer and pre-cancer painlessly and non-invasively, by analyzing the
wavelengths of light reflected from cervical tissue. The technology
distinguishes between normal and diseased tissue by detecting biochemical and
morphological changes at the cellular level. Unlike Pap or HPV tests, the
LightTouch test does not require a tissue sample or laboratory analysis, and is
designed to provide results immediately. The technology is designed as a device
employing a single-use disposable patient interface.

Organized and funded by the National Cancer Institute, ALTS included more than
5,000 women. It began in November 1996 and concluded at the end of 2000. ALTS
was a clinical trial to find the best way to help women and their doctors decide
what to do about the mildly abnormal and very common Pap test results known as
ASCUS and LSIL. About three million women in the United States are diagnosed
with ASCUS and LSIL each year.

Since development of the LightTouch began, more than 3,000 women have been
tested with the LightTouch, including approximately 2,000 women who were
enrolled in GT`s FDA pivotal clinical trial.

According to studies published in the peer-reviewed Journal of Lower Genital
Tract Disease, the non-invasive LightTouch test has the potential to be
significantly more accurate when compared to tissue sample-based tests such as
Pap and HPV.

About Guided Therapeutics

Guided Therapeutics, Inc. (Pink Sheets: GTHP) is developing a rapid and painless
test for the early detection of disease that leads to cervical cancer. The
technology is designed to provide an objective result at the point of care,
thereby improving the management of cervical disease. Unlike Pap and HPV tests,
the device does not require a painful tissue sample and results are known
immediately. GT also has an agreement with Konica Minolta Opto, Inc. (KMOT) of
Tokyo to co-develop non-invasive products, for the detection of lung and
esophageal cancer based on the company`s LightTouch non-invasive cervical cancer
detection technology. For more information, visit GT`s web site
www.guidedinc.com.

The Guided Therapeutics LightTouch Non-invasive Cervical Cancer Detection Device
is an investigational device and is limited by federal law to investigational
use.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995. A number of the matters and subject areas discussed in this news release
that are not historical or current facts deal with potential future
circumstances and developments. The discussion of such matters and subject areas
is qualified by the inherent risks and uncertainties surrounding future
expectations generally and also may materially differ from Guided Therapeutics`
actual future experience involving any of or more of such matters and subject
areas. Such risks and uncertainties include: the early stage of products in
development, the uncertainty of market acceptance of products, the uncertainty
of development or effectiveness of distribution channels, the intense
competition in the medical device industry, the uncertainty of capital to
develop products, the uncertainty of regulatory approval of products, dependence
on licensed intellectual property, as well as those that are more fully
described from time to time under the heading "Risk Factors" in Guided
Therapeutics` reports filed with the SEC, including Guided Therapeutics` Annual
Report on Form 10-KA for the fiscal year ended December 31, 2008 and subsequent
quarterly reports.

Guided Therapeutics, Inc.
Bill Wells, 770-242-8723

Copyright Business Wire 2009